Skip to main content
. 2021 Jan 29;36(7):2074–2084. doi: 10.1007/s11606-020-06504-8

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

a Target-mediated drug–drug interactions of cannabidiol with cannabinoid and 5-hydroxytryptamine 1A receptors27. b Target-mediated drug–drug interactions of cannabidiol with 5-hydroxytryptamine 2A receptors27. c Target-mediated drug–drug interactions of cannabidiol with 5-hydroxytryptamine 3A receptors27. d Target-mediated drug–drug interactions of cannabidiol with prostaglandin G/H synthase 1 and 2 inhibitors27. e Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 1B1 and 3A5 inhibitor27. f Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 2D6 and 3A7 inhibitor27. g Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 1A2 inhibitor27. The red dotted lines indicate CBD’s mechanism/actions as listed in red boxes. The blue double-headed arrows indicate the possible targets and interactions of CBD with other targets/mechanisms as listed in blue boxes. Green single-headed arrows indicate the drugs that act on these targets, as listed in green boxes. Such drugs may have additive/synergistic or antagonistic effects if given concomitantly with CBD.